Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Classical hematology 1Breast 1

Conditions

Breast Neoplasms 5Ovarian Neoplasms 3Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Hereditary Breast and Ovarian Cancer Syndrome 2Urogenital Neoplasms 1Sarcoma 1Pancreatic Neoplasms 1Neoplastic Syndromes, Hereditary 1Neoplasms, Unknown Primary 1Melanoma 1Kidney Neoplasms 1Head and Neck Neoplasms 1Fanconi Anemia, Complementation Group D1 1Digestive System Neoplasms 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms, Male 1Brain Neoplasms 1

Interventions

olaparib 4Carboplatin 2talazoparib 1pembrolizumab 1Surveys and Questionnaires 1Paclitaxel 1Genotype 1Genetic Counseling 1Demography 1Data Collection 1Counseling 1Cognitive Behavioral Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fanconi Anemia, Complementation Group D1 × Genetic Counseling × Breast × Clear all
NCT00165152 2012-08-09

Counseling Interventions for BRCA 1/2 Cancer Susceptibility Testing

Dana-Farber Cancer Institute

Phase NA Completed
150 enrolled
BreastClassical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Breast Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡